Apomorphine in off state - Clinical experience;Apomorfina w stanach off - Doświadczenia kliniczne

Neurologia i Neurochirurgia Polska

Volumn 41, Issue 2 SUPPL. 1, 2007, Pages

  Rudzińska, Monika ^a,b   Szczudlik, Andrzej ^b  

^a UNIVERSITY HOSPITAL IN KRAKOW   (Poland)

^b JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

Author keywords

Apomorphine; Off state treatment; Parkinson's disease

Indexed keywords

ADRENERGIC RECEPTOR; APO GO; APOFIN; APOMORPHINE; DOMPERIDONE; DOPAMINE; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; DOPAMINE 5 RECEPTOR; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; SEROTONIN RECEPTOR; TRIMETHOBENZAMIDE; UNCLASSIFIED DRUG;

ADD ON THERAPY; ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTINUOUS INFUSION; DELUSION; DRUG ABSORPTION; DRUG COST; DRUG EFFICACY; DRUG INDICATION; DRUG INTERMITTENT THERAPY; DRUG MECHANISM; DRUG RESPONSE; DYSKINESIA; EDEMA; HALLUCINATION; HUMAN; MONOTHERAPY; NAUSEA; ORTHOSTATIC HYPOTENSION; PARKINSON DISEASE; RECEPTOR AFFINITY; SIDE EFFECT; SKIN NODULE; SLEEP DISORDER; UNSPECIFIED SIDE EFFECT; VOMITING; YAWNING;

EID: 34248584625     PISSN: 00283843     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. Millan M.J., Maiofiss L., Cussac D. i wsp. Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes. J Pharmacol Exp Ther 2002; 303: 791-804.
2. Deleu D., Hanssens Y., Northway M.G. Subcutaneous apomorphine an evidence-based review of its use in Parkinson's disease. Drugs Aging 2004; 21: 687-709.
3. LeWitt P.A. Subcutaneously administered apomorphine: pharmacokinetics and metabolism. Neurology 2004; 62 (supl. 4): S8-11.
4. Hardie R.J., Lees A.J., Stern G.M. On-off fluctuations in Parkinson's disease: a clinical and neuropharmacological study. Brain 1984; 107: 487-506.
5. Hagell F., Odin P. Apomorphine in the treatment of Parkinson's disease. J Neurosci Nurs 2001; 33: 21-34.
6. Hughes A.J., Lees A.J., Stern G.M. Apomorphine test to predict dopaminergic responsiveness in parkinsonian syndromes. Lancet 1990; 336: 32-34.
7. Hughes A.J., Lees A.J., Stern G.M. Challenge test to predict the dopaminergic response in untreated Parkinson's disease. Neurology 1991; 41: 1723-1725.
8. Matthiessen A., Wright C.R. Researches into the chemical constitution of the opium bases. Part 1: on the action of hydrochloric acid on morphia. Proc R Soc Lond B Biol Sci 1868; 17: 455-460.
9. Neumeyer J.L., Lal S., Baldessarini R.J. Historical highlights of the chemistry pharmacology and early clinical uses of apomorphine. W: Gessa G.L., Corsini G.U. [red.]. Apomorphine and other dopaminomimetics. Vol 1. Basic pharmacology Raven Press, New York 1981, ss. 1-17
10. Gottlieb S. FDA committee recommends approval for viagra rival. BMJ 2000; 320: 1094.
11. Schwab R.S., Amador L.V., Lettvin J.Y. Apomorphine in Parkinson's disease. Trans Am Neurol Assoc 1951; 56: 251-253.
12. Cotzias G.C., Papavasiliou P.S., Tolosa E.S. i wsp. Similarities between neurologic effects of L-dopa and apomorphine. N Engl J Med 1970; 282: 31-32.
13. Duby S.E., Cotzias G.C., Papavasiliou P.S. i wsp. Injected apomorphine and orally administered levodopa in Parkinsonism. Arch Neurol 1972; 27: 474-480.
14. Hughes A.J., Bishop S., Kleedorfer B. i wsp. Subcutaneous apomorphine in Parkinson's disease: response to chronic administration for up to five years. Mov Disord 1993; 8: 165-170.
15. Pietz K., Hagell P., Odin P. Subcutaneous apomorphine in late stage Parkinson's disease: a long term follow up. J Neurol Neurosurg Psychiatry 1998; 65: 709-716.
16. Gancher S.T., Nutt J.G. Diurnal responsiveness to apomorphine. Neurology 1987; 37: 1250-1253.
17. Gancher S.T., Woodward W.R., Boucher B. i wsp. Peripheral pharmacokinetics of apomorphine in humans. Ann Neurol 1989; 26: 232-238.
18. Gancher S.T., Woodward W.R., Gliessman P. i wsp. The short - duration response to apomorphine: implications for the mechanism of dopaminergic effects in parkinsonism. Ann Neurol 1990; 27: 660-665.
19. Gancher S. Pharmacokinetics of apomorphine in Parkinson's disease. J Neural Transm Suppl 1995; 45: 137-141.
20. Cotzias G.C., Papavasiliou P.S., Tolosa E.S. i wsp. Treatment of Parkinson's disease with apomorphines: possible role for growth hormone. N Engl J Med 1976; 294: 567-572.
21. Neef C., van Laar T. Pharmacokinetic-pharmacodynamic relationships of apomorphine in patients with Parkinson's disease. Clin Pharmacokinet 1999; 37: 257-271.
22. Cotzias G.C., Papavasiliou P.S., Tolosa E.S. i wsp. Treatment of Parkinson's disease with aporphines. Possible role of growth hormone. N Engl J Med 1976; 294: 567-572.
23. Junginger H.E. Iontophoretic delivery of apomorphine: from in-vitro modelling to the Parkinson patient. Adv Drug Deliv Rev 2002; 54 (supl. 1): S57-75.
24. Dewey R.B. Jr, Maraganore D.M., Ahlskog J.E. i wsp. Intranasal apomorphine rescue therapy for parkinsonian "off" periods. Clin Neuropharmacol 1996; 19: 193-201.
25. Dewey R.B. Jr, Maraganore D.M., Ahlskog J.E. i wsp. A double-blind, placebo-controlled study of intranasal apomorphine spray as a rescue agent for off-states in Parkinson's disease. Mov Disord 1998; 13: 782-787.
26. Kleedorfer B., Turjanski N., Ryan R. i wsp. Intranasal apomorphine in Parkinson's disease. Neurology 1991; 41: 761-762.
27. Durif F., Deffond D., Dordain G. i wsp. Apomorphine and diphasic dyskinesia. Clin Neuropharmacol 1994; 17: 99-102.
28. Montastruc J.L., Rascol O., Senard J.M. Sublingual apomorphine in Parkinson's disease: a clinical and pharmacokinetic study. Clin Neuropharmacol 1991; 14: 432-437.
29. Koller W., Stacy M. Other formulations and future considerations for apomorphine for subcutaneous injection therapy. Neurology 2004; 62 (supl. 4): S22-26.
30. Van Laar T., Jansen E.N., Neef C. i wsp. Pharmacokinetics and clinical efficacy of rectal apomorphine in patients with Parkinson's disease: a study of five different suppositories. Mov Disord 1995; 10: 433-439.
31. Hughes A.J., Bishop S., Lees A.J. i wsp. Rectal apomorphine in Parkinson's disease. Lancet 1991; 337: 118.
32. Manson A.J., Hanagasi H., Turner K. i wsp. Intravenous apomorphine therapy in Parkinson's disease: clinical and pharmacokinetic observations. Brain 2001; 124: 331-340.
33. Goetz C., Poewe W., Rascol O. i wsp. Evidence-based medical review update: pharmacological and surgical treatments of Parkinson's disease: 2001 to 2004. Mov Disord 2005; 20: 523-539.
34. Braham J., Sarova-Pinhas I., Goldhammer Y. Apomorphine in Parkinsonian tremor. Br Med J 1970; 3: 768.
35. Factor S.A., Brown D.L., Molho E.S. Subcutaneous apomorphine injections as a treatment for intractable pain in Parkinson's disease. Mov Disord 2000; 15: 167-169.
36. Christmas T.J., Kempster P.A., Chapple C.R. i wsp. Role of subcutaneous apomorphine in parkinsonian voiding dysfunction. Lancet 1988; 2: 1451-1453.
37. Edwards L.L., Quigley E.M., Harned R.K. i wsp. Defecatory function in Parkinson's disease: response to apomorphine. Ann Neurol 1993; 33: 490-493.
38. Broussolle E., Marion M.H., Pollak P. Continuous subcutaneous apomorphine as replacement for levodopa in severe parkinsonian patients after surgery. Lancet 1992; 340: 859-860.
39. Frankel J.P., Lees A.J., Kempster P.A. i wsp. Subcutaneous apomorphine in the treatment of Parkinson's disease. J Neurol Neurosurg Psychiatry 1990; 53: 96-101.
40. Factor S.A. Literature review: intermittent subcutaneous apomorphine therapy in Parkinson's disease. Neurology 2004; 62 (supl. 4): 512-17.
41. Stocchi F., Vacca L., De Pandis M.F. i wsp. Subcutaneous continuous apomorphine infusion in fluctuating patients with Parkinson's disease: long-term results. Neurol Sci 2001; 22: 93-94.
42. Merello M., Pikielny R., Cammarota A. i wsp. Comparison of subcutaneous apomorphine versus dispersible madopar latency and effect duration in Parkinson's disease patients: a double-blind single-dose study. Clin Neuropharmacol 1997; 20: 165-167.
43. Dewey R.B. Jr, Hutton J.T., LeWitt P.A. i wsp. A randomized, double-blind, placebo-controlled trial on subcutaneously injected apomorphine for parkinsonian off-state events. Arch Neurol 2001; 58: 1385-1392.
44. Swope D. Rapid treatment of "wearing off" in Parkinson's disease. Neurology 2004; 62 (supl. 4): S27-31.
45. Rossi P., Colosimo C., Moro E. i wsp. Acute challenge with apomorphine and levodopa in Parkinsonism. Eur Neurol 2000; 43: 95-101.
46. Clarke C.E., Davies P. Systematic review of acute levodopa and apomorphine challenge tests in the diagnosis of idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry 2000; 69: 590-594.
47. Apomorphine for the Management of Motor Fluctuations in Parkinson's Disease. A CME monograph based on a Kickoff Seminar held at The Movement Disorder Society's 9th International Congress of Parkinson's Disease and Movement Disorders. New Orleans, Louisiana, March 5, 2005.